Large consumer packaged goods (CPG) companies find it cheaper and faster to acquire startups with proven products rather than innovate internally. This "M&A beats R&D" model is specific to sectors like food and beauty, unlike the auto industry where internal R&D is critical for competition.

A restrictive stance on mergers and acquisitions stifles the entire startup ecosystem by removing viable exit paths. Allowing M&A to flourish provides the liquidity events that encourage venture capitalists to deploy risk capital into the next generation of innovative companies.

Mergers and acquisitions are more than just exits for private biotech companies. They are the primary mechanism for returning capital to venture capitalists and LPs, who then reinvest those funds back into the ecosystem, fueling the next generation of innovative startups.

Regulatory crackdowns on M&A have a chilling effect far beyond the companies involved. When successful startups can't exit via acquisition, capital gets trapped. This prevents VCs from returning money to LPs, who in turn can't fund the next generation of founders, grinding the innovation engine to a halt.

Large pharma mergers are a net negative for biotech startups. When two giants combine, they become internally focused on integration for 2-3 years, effectively removing two active buyers from the M&A landscape and reducing exit opportunities for the entire ecosystem.

Large corporations like PepsiCo have effectively outsourced innovation, avoiding the risk of building new brands by acquiring successful startups like Poppi. This dynamic creates a clear and lucrative exit path for entrepreneurs who can build the "next big thing," as they are creating acquisition targets, not just competitors.

When an industry is threatened by an external force like AI, consolidation is a key defensive strategy. Ironically, this is when regulators are most likely to intervene. Because these declining companies are knowable and easy to analyze, it makes it easier for regulators to block deals, preventing a necessary survival response.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.

The famed Tobacco Master Settlement Agreement did not end the industry. Instead, it spurred consolidation and prompted companies to innovate into new, less-regulated products like e-cigarettes and pivot to less-regulated international markets, showing the limitations of such landmark settlements.